Melissa R Junttila
机构: ORIC Pharmaceuticals
每年引用次数
引用次数
引用: 11,503
H-指数: 38
I10-指数 : 46
出版物: 109
Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
Melissa R. Junttila , Vidusha Devasthali , Jason H. Cheng , Joseph Castillo
Molecular Cancer Therapeutics 14 ( 1) 40 -47
45
2015
p53 — a Jack of all trades but master of none
Melissa R. Junttila , Gerard I. Evan
Nature Reviews Cancer 9 ( 11) 821 -829
266
2009
Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1
Anni Laine , Harri Sihto , Christophe Come , Mathias T. Rosenfeldt
Cancer Discovery 3 ( 2) 182 -197
89
2013
Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival
Melissa R Junttila , Song‐Ping Li , Jukka Westermarck ,
The FASEB Journal 22 ( 4) 954 -965
951
2008
Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.
Xiaohui Du , Jared Moore , Brian R. Blank , John Eksterowicz
Journal of Medicinal Chemistry 63 ( 18) 10433 -10459
3
2020
Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous
Wei-Jen Chung , Anneleen Daemen , Jason H. Cheng , Jason E. Long
Proceedings of the National Academy of Sciences of the United States of America 114 ( 51) 201708391
36
2017
Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis
Kai H. Barck , Hani Bou-Reslan , Ujjawal Rastogi , Timothy Sakhuja
Translational Oncology 8 ( 2) 126 -135
5
2015
RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases.
Jason H. Cheng , Juan Zhang , Debra L. Dugger , Kate E. Wickliffe
Cell Death & Differentiation 27 ( 1) 161 -175
37
2020
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Anchit Khanna , Camilla Böckelman , Annabrita Hemmes , Melissa R. Junttila
Journal of the National Cancer Institute 101 ( 11) 793 -805
156
2009
Abstract PO-099: SOX2 delineates a mouse lung adenocarcinoma subtype vulnerable to targeted therapy
Jonathan E. Cooper , Anneleen Daemen , Dorothee Nickles , Szymon Myrta
Cancer Research 80
2020
Abstract PO-101: Transcriptional heterogeneity in lung adenocarcinoma reveals distinct therapeutic vulnerabilities
Anneleen Daemen , Jonathan E. Cooper , Szymon Myrta , Matthew J. Wongchenko
Cancer Research 80
2020
BIM Is the Primary Mediator of MYC-Induced Apoptosis in Multiple Solid Tissues
Nathiya Muthalagu , Melissa R. Junttila , Katrin E. Wiese , Elmar Wolf
Cell Reports 8 ( 5) 1347 -1353
48
2014
Mechanisms of MYC stabilization in human malignancies
Melissa R. Junttila , Jukka Westermarck
Cell Cycle 7 ( 5) 592 -596
121
2008
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel VT Catenacci , Melissa R Junttila , Theodore Karrison , Nathan Bahary
Journal of Clinical Oncology 33 ( 36) 4284 -4292
449
2015
Single‐step Strep‐tag® purification for the isolation and identification of protein complexes from mammalian cells
Melissa R. Junttila , Susanna Saarinen , Thomas Schmidt , Juergen Kast
Proteomics 5 ( 5) 1199 -1203
107
2005
Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/β-Catenin Pathway Activation
Andrew J. Finch , Laura Soucek , Melissa R. Junttila , Lamorna Brown Swigart
Molecular and Cellular Biology 29 ( 19) 5306 -5315
63
2009
Lymph node-independent liver metastasis in a model of metastatic colorectal cancer
Ida B. Enquist , Zinaida Good , Adrian M. Jubb , Germaine Fuh
Nature Communications 5 ( 1) 3530
34
2014
Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment.
Johannes Riegler , Yassin Labyed , Stephen Rosenzweig , Vincent Javinal
Clinical Cancer Research 24 ( 18) 4455 -4467
32
2018
S02-05 Targeting tumor suppressor pathways to treat cancer
Carla Martins , Ksenya Schors , Melissa Junttila , Daniel Garcia
Mechanisms of Development 126 S27
2009
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.
Marie-Claire Wagle , Daniel Kirouac , Christiaan Klijn , Bonnie Liu
npj Precision Oncology 2 ( 1) 1 -12
36
2018